Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Thelin sitaxsentan: Completed Phase II enrollment

ENCY completed enrollment of 150 patients in a double-blind,

Read the full 98 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE